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Abstract
An outbreak of echovirus 5 (ECV 5) occurred in Korea in 2006, marking the first time this virus had been identified
in the country since enterovirus surveillance began in 1993. Using a sample isolated from a young male patient
with aseptic meningitis, we performed sequencing of the Korean ECV 5 strain and compared it with a prototype
strain (Noyce). At the nucleotide level, the P1 region (85.3%) had the highest identity value; at the amino acid level,
the P3 region (98.0%) had the highest identity value. The two strains shared all cleavage sites, with the exception
of the VP1/2A site, which was TY/GA in the Noyce strain but TR/GA in the Korean ECV 5 isolate. In Vero cells
infected with the Korean ECV 5 isolate, no cytotoxicity was observed in the presence of azidothymidine, acyclovir,
amantadine, lamivudine, or ribavirin, when the drugs were administered at a CC50 value >100 μg/mL. Of the five
drugs, only amantadine (IC50: 1 ± 0.42 μg/mL, TI: 100) and ribavirin (IC50: 22 ± 1.36 μg/mL, TI: 4.55) had any antiviral
activity against the Korean ECV 5 isolate.
1. Introduction
Human enteroviruses (HEV) are RNA viruses from the
Picornaviridae family. The 80 immunologically-distinct
serotypes that are known to cause infections in humans
can be grouped as follows: polioviruses (PV), echoviruses
(ECV), coxsackieviruses A (CVA), coxsackieviruses B
(CVB), and enterovirus (EV) types 68-71. These viruses
are also classified genetically into five species (HEV-A to
HEV-D and PVs). HEV-B group containing ECV 5 are
CBV 1 to 6, CVA9, ECV 1 to ECV 7, ECV 9, ECV 11 to
ECV 21, ECV 24 to ECV 27, ECV 29 to 33, EV 69, EV 73
[1-5].
ECV cause the same types of infections in humans as
the CVB group, but are given a distinct classification
primarily because they lack pathogenicity in newborn
mice [6]. There are, however, strains of ECV that are
pathogenic in mice [7]. ECV 5 infections have been
associated with a wide variety of neurological and
exanthematic diseases. The prototype strain of ECV 5
was isolated from a patient with aseptic meningitis and
was later grouped as the fifth enterovirus serotype [8].
An outbreak of aseptic meningitis caused by ECV 5
occurred in Korea in 2006, marking the first time that
ECV 5 had been identified in the country since entero-
virus surveillance began in 1993 [9].
The ECV 5 genome contains approximately 7,500
nucleotide-long single-stranded RNA molecules with
polarity and carries a small viral peptide (VPg) covalently
attached to its 5’ end. The 5’ untranslated region (UTR)
of the RNA is approximately 700 nt in length and is unu-
sually long compared with the homologous region of cel-
lular mRNA. The internal ribosomal entry site (IRES)
was discovered in the 5’ UTR of the HEVs. In these
viruses, the IRES can fold to be a functional secondary
RNA structure and drive translation initiation [10]. The
coding region encompasses a single open reading frame
that encodes a polyprotein divided into three sub-regions,
P1, P2, and P3. The P1 region encodes the genetic infor-
m a t i o no ff o u rs t r u c t u r a lp r o t e i n s ,V P 4 ,V P 2 ,V P 3 ,a n d
VP1. The non-structural proteins are encoded in the P2
( 2 A - 2 C )a n dP 3( 3 A - 3 D )r e g i o n s .As h o r t3 ’ UTR of
approximately 100 nt separates the coding region from
the poly (A) tail [6,11].
At present, some 40 antiviral drugs have been formally
licensed for use in humans, mostly for treatment of
human immunodeficiency virus, hepatitis B virus, and
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that have been licensed for use in treating highly-
pathogenic RNA virus infections is very limited; the
current list of approved drugs includes anti-influenza
medications, M2 channel inhibitors (amantadine and
rimantadine), and neuramidase inhibitors (oseltamivir
and zanaminir). Ribavirin is licensed for the treatment
of respiratory syncytial virus and hepatitis C virus infec-
tions [12,13]. Pleconaril, an antiviral drug developed in
1996 for treatment of diseases associated with picorna-
virus infections, can be used in treatments against enter-
ovirus and rhinovirus infections [14]. However, the
treatment of this drug was extremely limited and
reported to pleconaril-resistant viruses [15,16].
In this study, the molecular biological characteristics
and genetic diversity of Korean ECV 5 that do not exist
the using antiviral agents for it but widespread currently
were analyzed through the complete nucleotide sequen-
cing and compared with ECV 5 prototype strain (Noyce).
We also selected 5 kinds of antiviral drugs (azidothymi-
dine, acyclovir, amantadine, lamivudine, and ribavirin)
that were used as inhibitors of other viruses and exam-
ined for anti-viral activity for Korean ECV 5.
2. Materials and methods
2.1 Virus isolation and identification
The Korean ECV 5 strain was isolated from cerebrosp-
inal fluid sampled from a male patient with aseptic
meningitis who had been admitted to the Department of
Pediatrics at the Soonchunhyang University Cheonan
Hospital, Korea, in June 2006. The sample was inocu-
lated into Vero cells and then incubated at 37°C with
5% CO2 until the appearance of cytopathic effects (CPE)
took place. The identification of the Korean isolate was
verified by a Basic Local Alignment Search Tool
(BLAST) search in VP1 sequences; that is, the VP1
sequences of Korean isolate had the highest nucleotide
similarity with ECV5 serotype strains [3].
2.2 Nucleotide sequencing and sequence analysis
The complete nucleotide sequence of the Korean ECV 5
strain was determined using a primer walking strategy;
the sequences of the genome termini were determined
by random amplification of cDNA ends (RACE) system
(Invitrogen, Carlsbad, CA, USA). The PCR products
were purified using a QIAquick PCR Purification Kit
(Qiagen, Hamburg, Germany). The purified DNA was
added to a reaction mixture containing 2 μLo fB i gD y e
terminator reaction mix (ABI Prism BigDye Terminator
Cycle Sequencing Kit; Applied Biosystems, Foster, CA,
USA) and 2 pmoles of each primer. Sequencing reac-
tions were subjected to an initial denaturation at 96°C
for 1 min and 25 cycles consisting of 96°C for 10 sec,
50°C for 5 sec, and 60°C for 4 min in a Gene Amp PCR
system 2700 (Applied Biosystems). The products were
purified by precipitation with 100% cold ethanol and
3 M sodium-acetate (pH 5.8), then loaded on an auto-
mated 3100 Genetic Analyzer (Applied Biosystems).
Nucleotide sequences of enterovirus isolates were con-
structed to contig and were compared with a reference,
the Noyce (Accession no. AF083069) strain, which was
originally identified in the USA in 1954, and the nucleo-
tide sequence of which was obtained from Genbank
databases [17]. Sequence analyses were performed using
computer software included in the Lasergene package
(DNASTAR, Inc., Madison, WI, USA).
2.3 Antiviral drugs and antiviral activity assays
Assays of antiviral activity and cytotoxicity were evalu-
ated by the modified sulforhodamine B (SRB) assay pre-
viously described and recently reported by Choi et al
[18-20]. Ribavirin was purchased from DUCHEFA
(Netherlands); azidothymidine, acyclovir, amantadine,
and lamivudine were purchased from Sigma-Aldrich
(St. Louis, MO, USA), as was SRB.
One day before infection, Vero cells were seeded onto
a 96-well culture plate at a concentration of 2 × 10
4
cells per well. Next day, the medium was removed and
then washed with 1 × phosphate buffered saline (PBS).
Infectivity of the virus stock was determined by the SRB
method and was determined as infectivity of the virus
by SRB ID50 (50% infective dose). Following this,
0.09 mL of diluted virus suspension of ECV containing
CCID50 (50% cell culture infective dose) of the virus
stock to produce an appropriate cytopathic effects
within 2 days after infection and 0.01 mL of medium
containing an appropriate concentration of the com-
pounds were added. The antiviral activity of each test
material was determined with a 10-fold diluted concen-
tration ranging from 0.1 to 100 μL/mL. Three wells
were used as virus controls (virus-infected non-drug-
treated cells) while three wells were used as cell controls
(non-infected non-drug-treated cells). The culture plates
w e r ei n c u b a t e da t3 7 ° Ci n5 %C O 2 for 2 days. After
washing once with 1 × PBS, 100 μL of cold (-20°C), 70%
acetone was added to each well and left for 30 min at
-20°C. 70% acetone was removed and 96-well plates
were left at dry oven for 30 min. 100 μLo f0 . 4 %( w / v )
SRB in 1% acetic acid solution was added to each well
and left at room temperature for 30 min. Unbound SRB
was removed and the plates were washed 5 times with
1% acetic acid before oven drying and were then left in
a dry oven for 1 day. Bound SRB was solubilized with
100 μL of 10 mM unbuffered tris-base solution and
plates were left on a table for 30 min. The absorbance
was read at 540 nm by using a VERSAmax microplate
reader (Molecular Devices, Palo Alto, CA, USA) with a
reference absorbance at 620 nm. To calculate the IC50
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Page 2 of 5(50% inhibitory concentration) values, the results were
transformed to percentage of controls and the IC50
values were graphically obtained from the dose-response
curves. The percent protection achieved by the test
compound in ECV-infected cells was calculated by the
following formula:
() ()
() ()
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OD OD
1  (Expressed i tE C V  5 cE C V  5
cm o c k cE C V  5
−
−
× 00 n n ) %
where (ODt)ECV is the optical density measured with
a given concentration of the test compound in ECV-
infected cells; (ODc)ECV is the optical density mea-
sured for the control untreated ECV-infected cells;
and (ODc)mock is the optical density measured for con-
trol untreated mock-infected cells. The therapeutic
index was defined as 50% cytotoxic concentration
(CC50)/IC50.
2.4 Cytotoxicity assay
Vero cells were seeded into a 96-well culture plate at a
concentration of 2 × 10
4 cells per well. Next day, the
medium was removed and the 96-well plates were
replaced with media containing the serially diluted com-
pounds, and the cells were further incubated for 48 hrs.
The culture medium was removed and washed with 1 ×
PBS. The next step was conducted by antiviral activity
assay described above. To calculate the CC50 values, the
results were transformed to percentage of controls and
the CC50 values were graphically obtained from the
dose-response curves.
3. Results
3.1 Complete nucleotide sequence of Korean ECV5
The Korean ECV 5 genome was sequenced (GenBank
accession number HM775882) and its amino acid
sequence was deduced. The genome is 7,430 nt in length,
excluding the poly(A) tail. The 5’NCR contains 738 nt,
followed by an ORF that encodes a viral polyprotein con-
sisting of 2,196 codons, between a start codon (AUG) at
position 739 and a stop codon (UGA) at position 7,326.
The 3’NCR is 104 nt in length (Table 1).
3.2 Genome comparison between Korean ECV5 and the
Noyce strain
The Korean ECV 5 isolate genome was divided into five
regions (5’NCR, P1, P2, P3, and 3’NCR) and aligned
with the Noyce strain using Megalign (DNASTAR). The
P1 region (85.3%) had the highest level of nucleotide
identity, followed by the P3 region (84.8%), the 3’NCR
(84.5%), the 5’NCR (81.8%), and the P2 region (80.0%).
The P3 region (98.0%) had the highest level of amino
acid identity, followed by the P1 region (97.7%), and the
P2 region (96.9%).
Most of the cleavage sites were identical between Kor-
ean ECV 5 and the Noyce strain. The only exception
was the cleavage site between VP1 and 2A, which was
TY/GA in the Noyce strain, but TR/GA in the Korean
ECV 5 isolate (Table 1).
3.3 Antiviral activity of Korea ECV5
No signs of cytotoxicity were observed in Vero cells
treated with any of the five antiviral drugs at a CC50
Table 1 Genome components of the Korean echovirus 5 (ECV 5) isolate and comparison of predicted N-terminal
cleavage sites for the Korean ECV 5 isolate and the Noyce strain
Region Nucleotide sequence Amino acid sequence Predicted N-terminal cleavage sites
start end length start end length Kor-ECV5 Noyce
5’NCR 1 738 738 - - - - -
Polyprotein 739 7326 6588 1 2196 2196 - -
P1 739 3324 2586 1 862 862 - -
P2 3325 5058 1734 863 1440 578 TR/GA TY/GA
P3 5059 7326 2268 1441 2196 756 FQ/GP FQ/GP
VP4 739 945 207 1 69 69 - -
VP2 946 1731 786 70 331 262 LN/SP LN/SP
VP3 1732 2448 717 332 570 239 PQ/GL PQ/GL
VP1 2449 3324 876 571 862 292 LQ/GD LQ/GD
2A 3325 3774 450 863 1012 150 TR/GA TY/GA
2B 3775 4071 297 1013 1111 99 EQ/GV EQ/GV
2C 4072 5058 987 1112 1440 329 RQ/NN RQ/NN
3A 5059 5355 267 1441 1529 89 FQ/GP FQ/GP
3B 5356 5421 66 1530 1551 22 FQ/GA FQ/GA
3C 5422 5970 549 1552 1734 183 VQ/GP VQ/GP
3D 5971 7326 1386 1735 2196 462 EQ/GE EQ/GE
3’NCR 7327 7430 104 - - - - -
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Page 3 of 5value >100 μg/mL. Amantadine and ribavirin exhibited
antiviral activity against the Korean ECV 5 strain,
though azidothymidine, acyclovir, and lamivudine did
not. The amantadine possessed an IC50 value of 1 ±
0.42 μg/mL and a TI value of 100, while the ribavirin
possessed an IC50 v a l u eo f2 2±1 . 3 6μg/mL and a TI
value of 4.55 (Table 2 and Figure 1).
4. Discussion
The ECV 5 is a rare enterovirus strain as causative asep-
tic meningitis and its sequence information is not com-
mon in the previous publication, including genbank
database. This report describes the first complete nucleo-
tide sequence for an ECV 5 isolated in Korea. Previous
work has shown that sequence identity between different
ECV serotypes is relatively high for the 5’NCR sequence,
moderate for the P2 and P3 regions, and lowest for the
P1 region [21]. This was not the pattern that emerged
when we compared the Korean ECV 5 isolate and the
Noyce strain; rather, the 5’NCR and P2 regions had rela-
tively low nucleotide sequence identities (<81.8%), while
the identities of the P1 and P3 regions were relatively
high (>84.5%). Amino acid sequences for the protein cod-
ing regions had much higher sequence identities
(>96.9%). Cleavage site variations have often been
reported for VP2/VP3, VP3/VP1, and VP1/2A [21,22].
Thus, we were not surprised to find that, though conser-
vation was observed at most sites, there had been a sub-
stitution (TY/GA®TR/GA) at VP1/2A. There was about
2 0 %g e n e t i cd i f f e r e n c eb e t w e e np r o t o t y p ea n dt h ec u r -
rent widespread strain, and its difference was found at
the cleavage site. Therefore, development and screening
of antiviral drugs have to be focused on the object of the
current epidemic strain.
Of the five antiviral drugs tested here (azidothymidine,
acyclovir, amantadine, lamivudine, and ribavirin), only
amantadine (IC50:1μg/mL) and ribavirin (IC50:2 2μg/
mL) had antiviral activity against Korean ECV 5, with
amantadine showing stronger effects than ribavirin.
Therefore, the amantadine and ribavirin could be
applied to patients infected with ECV 5. It was reported
that the amantadine could suppress the IRES mediated
translation, and ribavirin is a nucleoside analogue with
broad-spectrum antiviral activity by decreasing viral
replication in EV71 [23,24].
In conclusion, this manuscript is the first report of the
complete nucleotide sequence of the Korean ECV strain,
as well as the first examination of its response to various
antiviral drugs. This data should be useful in preventing
future outbreaks of ECV5 and in treating patients
infected with the strain. Accordingly, it is necessary to
test more of the same kind of antiviral drugs and var-
ious enterovirus serotypes in future studies.
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